Abstract
To the Editor: Boucher et al. (June 5 issue)1 report the results of DISCOVER 1 and DISCOVER 2, and in the same issue Corey et al.2 report the results of SOLO I. These randomized trials investigated the efficacy of oritavancin and dalbavancin in acute bacterial skin and skin-structure infections. We are concerned that the design of these studies and that of other pivotal studies are not consistent with clinical management of acute bacterial skin and skin-structure infections and that their results are thus not useful for clinical decisions in real life — at least in Europe and some other areas . . .
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
